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A diverse group of retroviral proteases were analyzed 
to correlate mechanisms of substrate recognition with 
resistance to HIV-1 protease active-site inhibitors. 
Here it was shown that HIV-1 protease utilized a path-
way common to many retroviral proteases, for recogni-
tion of mutated Gag/Pol cleavage sites, in order to be-
come resistant to active-site inhibitors. While HIV-1 
and HIV-2 resulted from independent cross-species 
transmissions of simian immunodeficiency virus into 
humans, HIV-2 has native primary resistance to many 
HIV-1 protease inhibitors as do many other retroviral 
proteases. The native multi-drug resistance of those 
proteases contributed to the lack of treatments for the 
respective life-long infections. Analysis of interactions 
between retroviral proteases and Gag/Pol substrates 
revealed that protease interactions weighted towards 
cleavage site residues P4-P4' resulted in inhibitor sen-
sitivity, while interactions weighted towards residues 
P12-P5/P5'-P12' gave inhibitor resistance. In addition, 
a mechanism was identified for human T-cell leukemia 
virus type-1 protease that allowed re-weighting of the 
protease interactions with substrate residues P4-P4' 
and P12-P5/P5'-P12' using anti-parallel beta-sheets 
that connected the protease flaps to the substrate-
grooves. Those anti-parallel beta-sheets are common to 
all studied retroviral proteases. The critical role of the 
retroviral protease substrate-grooves in substrate 
recognition and inhibitor resistance makes them a po-
tential target. 
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Introduction 
 
Retroviruses infect a remarkably diverse range of ver-
tebrate species that span fish to humans (Barre-
Sinoussi et al. 1983, Fodor & Vogt 2002, Gallo et al. 
1983). All retroviruses encode an aspartic acid prote-
ase (PR) in which two identical monomers each con-
tribute a catalytic aspartic acid residue to the active-
site of the symmetrical PR dimer (Kohl et al. 1988, 
Wlodawer et al. 1989). The retroviral PR is typically 
expressed as either a Gag-Pro polyprotein, or as a Gag-
Pro-Pol polyprotein, due to translational frame shifting 
near the C-terminus of Gag (Jacks et al. 1988). As the 
virus buds from the host cell, the PR first undergoes 
autocatalytic processing out of the respective polypro-
tein, and then cleaves Gag to release the structural pro-
teins that are needed for virion maturation: matrix; 
capsid; and nucleocapsid (Strickler et al. 1989). The 
PR also cleaves Pol to release the enzymes needed for 
completion of the viral replication cycle in the next 
host cell: reverse transcriptase and integrase (Strickler 
et al. 1989). The essential role of the HIV-1 PR in viri-
on maturation and activation of the viral enzymes have 
made the HIV-1 PR an important target in the treat-
ment of human immunodeficiency virus type-1 (HIV-
1) infections. Clinical HIV-1 PR inhibitors are typical-
ly peptidomimetics based in part on native cleavage 
sites; the only non-peptidomimetic inhibitor in current 
clinical use is tipranavir, which perhaps as a conse-
quence is associated with more severe adverse effects. 
The HIV-1 protease inhibitors are comparable in 
length to a four residue peptide substrate and are typi-
cally designed to bind to the HIV-1 PR active-site as a 
transition state mimetic with a water tetrahedrally co-
ordinated between the inhibitor P1/P1' backbone car-
bonyl oxygens and the backbone nitrogens of the HIV-
1 PR flaps, Figure 1. Novel side groups on the inhibi-
tors increase both van der Waals and H-bond interac-
tions with the HIV-1 PR active-site and that contrib-
utes to active-site inhibitors being able to outcompete 
Gag/Pol substrates for binding to HIV-1 PR (Erickson 
et al. 1990, Miller et al. 1989). 
 HIV-1 PR inhibitor resistance typically begins 
with the selection of primary mutations in the active-
site that can either reduce van der Waals contacts due 
to shorter side-chains (i.e., Ile54Val), or change the 
electrostatic interactions (i.e., Asp30Asn), between the 
HIV-1 PR and inhibitor, Figure 1 (Wensing et al. 
2015). Those active-site mutations can also decrease 
the interactions between HIV-1 PR and substrate resi-
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dues P4-P4’ resulting in reduced viral replicative ca-
pacity, Figure 2 (Chang & Torbett 2011, Gulnik et al. 
1995, Kaplan et al. 1994, Martinez-Picado et al. 1999, 
Nijhuis et al. 1999, Pazhanisamy et al. 1996, Prabu-
Jeyabalan et al. 2004, Schock et al. 1996). Next, selec-
tion of secondary resistance mutations distant from the 
active-site (i.e., Ala71Leu, Gly73Thr) restored both 
HIV-1 PR binding to Gag/Pol cleavage sites and viral 
replicative capacity while maintaining inhibitor re-
sistance, Figure 1 and 2 (Chang & Torbett 2011, 
Gulnik et al. 1995, Kaplan et al. 1994, Martinez-
Picado et al. 1999, Nijhuis et al. 1999, Pazhanisamy et 
al. 
1996, Prabu-Jeyabalan et al. 2004, Schock et al. 1996)  
 In order to gain insight into the evolution of 
multi-drug resistant HIV-1 PR (MDR HIV-1 PR) re-
searchers initially focused on understanding HIV-1 PR 
interaction with the ten primary Gag/Pol polyprotein 
cleavage sites by using short peptide substrates con-
taining Gag/Pol cleavage site residues P4-P4'. Howev-
er, a consistent cleavage order for the short peptides 
could not be determined in part because in order to 
increase peptide solubility researchers used different 
assay conditions and peptides of different lengths, in-
cluding non-native N-and C-terminal residues (Billich 
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Figure 1. WT HIV-1 PR bound to nelfinavir. A, HIV-1 PR front view with flaps on top, A and B subunits as backbone rib-
bons, active-site Asp25 (A and B subunits, center) with side chains atoms in: oxygen, red; carbon, grey. Nelfinavir (bronze, 
CPK rendering) bound in the active-site, hydrogens not shown. Tetrahedrally coordinated water (center, above nelfinavir) with 
all atoms in blue. Solid colored PR residues that when mutated contributed to either primary, or secondary, inhibitor resistance 
are shown only once on either the A or B subunits. Primary active-site residues in red, clockwise from center of left subunit: 
Asp30; Ile47; Met46; Gly48; Ile54; Ile50; Val82; Ile84. Secondary S-groove residues in bronze, clockwise from bottom of left 
subunit: Ala71; Gly73; Thr74; Asn88. Secondary cleavage-site residues with residue and cleavage site indicted in green, clock-
wise from bottom of left subunit: Ile93 (P7 PR/RT); Leu90 (P10 PR/RT); Leu10 (P10' p6*/PR); Val11, P11' (p6*/PR). B, HIV-
1 PR front view (flaps on top) with electrostatic surface potential (red negative, blue positive) and bound nelfinavir (bronze, 
CPK rendering). 
Figure 2. WT HIV-1 PR bound to Gag SP1/NC cleavage site 8-mer. A, HIV-1 PR front view with flaps on top, A and B 
subunits as backbone ribbons, active-site mutation D25N (A and B subunits, center) side chains atoms: oxygen, red; nitrogen 
blue; carbon, grey. SP1/NC cleavage site residues P4-P4' (bronze, CPK rendering) bound in the active-site, hydrogens not 
shown. Tetrahedrally coordinated water not visible (see Fig. 1 A). Solid colored PR residues that when mutated contributed to 
either primary, or secondary, inhibitor resistance are shown only once on either the A or B subunits. Primary active-site residues 
in red, clockwise from center of left subunit: Asp30; Ile47; Met46; Gly48; Ile54; Ile50; Val82; Ile84. Secondary S-groove resi-
dues in bronze, clockwise from bottom of left subunit: Ala71; Gly73; Thr74; Asn88. Secondary cleavage-site residues with resi-
due and cleavage site indicted in green, clockwise from bottom of left subunit: Ile93 (P7 PR/RT); Leu90 (P10 PR/RT); Leu10 
(P10' p6*/PR); Val11, P11' (p6*/PR). B, HIV-1 PR front view (flaps on top) with electrostatic surface potential (red negative, 
blue positive) and bound SP1/NC cleavage site residues P4-P4' (bronze, CPK rendering). 
et al. 1988, Darke et al. 1988, Kotler et al. 1988, 
Krausslich et al. 1989, Tozser et al. 1991). It was only 
when in vitro transcribed/translated full length Gag 
and Gag-Pro-Pol polyproteins and purified full-length 
Gag polyprotein were used as substrates for HIV-1 PR 
that a consistent cleavage order was determined 
(Erickson-Viitanen et al. 1989, Pettit et al. 2005). The-
se results indicated that cleavage site residues outside 
of P4-P4’ were important for HIV-1 PR recognition of 
substrates and provided a clue as to how the MDR 
HIV-1 PR evolved. More recently, it was shown that 
the HIV-1 PR can also bind the Gag MA/CA cleavage 
site residues P12-P5/P5’-P12’ (|P12-P5|) in the sub-
strate-grooves (S-grooves), one on each face of the 
symmetric HIV-1 PR dimer, Figure 3 (Laco 2015). In 
addition, recent NMR studies on HIV-1 PR interaction 
with Gag polyproteins revealed that residues in the 
HIV-1 PR S-grooves, as previously defined (Laco 
2015), interacted with Gag cleavage site residues out-
side of P4-P4' (Deshmukh et al. 2017). Here those 
findings were extended in silico to include the interac-
tion between WT and MDR HIV-1 PRs and nine Gag/
Pol cleavage sites represented as either 8-mers (P4-
P4’), or 24-mers (P12-P12’), to evaluate the im-
portance of the S-groove interaction with substrates, 
while eliminating the inherent variables of in vitro 
peptide cleavage assays. By understanding HIV-1 PR 
substrate interactions, a strategy can be developed to 
target HIV-1 that express MDR PR.  
 In contrast to HIV-1 PR where inhibitor re-
sistance can be selected for in vitro and in vivo, many 
other retroviruses express PRs with native resistance to 
HIV-1 PR active-site inhibitors. For example, whereas 
HIV-1 and HIV-2 originated from independent trans-
missions of simian immunodeficiency virus (SIV) into 
humans (Hirsch et al. 1989, Huet et al. 1990, Marx et 
al. 1991, Peeters et al. 1989), HIV-2 PR has native 
primary resistance to many HIV-1 PR clinical inhibi-
tors (Brower et al. 2008, Masse et al. 2007, Rodes et 
al. 2006, Witvrouw et al. 2004). Similarly, while hu-
man T-cell leukemia virus type-1 (HTLV-1) resulted 
from the cross species transmission of simian T-cell 
leukemia virus (STLV) into humans (Koralnik et al. 
1994, Voevodin et al. 1997), the HTLV-1 PR has na-
tive multi-drug resistance to HIV-1 PR inhibitors 
(Ding et al. 1998, Pettit et al. 1998). In addition, both 
equine infectious anemia virus (EIAV) and feline im-
munodeficiency virus (FIV) PRs have been reported to 
have native multi-drug resistance to HIV-1 PR inhibi-
tors (Kervinen et al. 1998). The native multi-drug re-
sistance of HTLV-1, EIAV, and FIV PRs is a key rea-
son why there are no effective treatments for the re-
spective life-long retroviral infections. In the case of 
HTLV-1, long-term untreated infections can result in 
several debilitating neurological diseases, as well as a 
rapidly progressing and terminal T-cell leukemia 
(Goncalves et al. 2010, Proietti et al. 2005). The pub-
lished structures of the above PRs allowed for the in 
silico analysis of the interactions between the PRs and 
both substrates and inhibitors, Results (Gustchina et al. 
1996, Kovalevsky et al. 2008, Laco et al. 1997, Li et 
al. 2005, Rose et al. 1996a). In addition, the generation 
of three-dimensional (3D) models of the HIV-1 Gag 
and Pol polyproteins provided insight into the role of 
cleavage site accessibility on PR recognition of sub-
strates. The analysis revealed the native resistance 
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Figure 3. WT HIV-1 PR bound to Gag SP1/NC cleavage site 24-mer. A, HIV-1 PR front view with flaps on top, A and B 
subunits as backbone ribbons, active-site mutation D25N (center, A and B subunits) side chains atoms: oxygen, red; nitrogen, 
blue, carbon, grey. SP1/NC cleavage site residues P12-P12' (bronze ribbon |P12-P5|, red ribbon P4-P4') bound in the active-site 
and S-grooves, hydrogens not shown. Tetrahedrally coordinated water (center, above substrate) with all atoms blue. Solid col-
ored PR residues that when mutated contributed to either primary, or secondary, inhibitor resistance are shown only once on 
either the A or B subunits. Primary active-site residues in red, clockwise from center of left subunit: Asp30; Ile47; Met46; 
Gly48; Ile54; Ile50; Val82; Ile84. Secondary S-groove residues in bronze, clockwise from bottom of left subunit: Ala71; 
Gly73; Thr74; Asn88. Secondary cleavage-site residues with residue and cleavage site indicted in green, clockwise from bot-
tom of left subunit: Ile93 (P7 PR/RT); Leu90 (P10 PR/RT); Leu10 (P10' p6*/PR); Val11, P11' (p6*/PR). B, HIV-1 PR front 
view with flaps on top and electrostatic surface potential (red negative, blue positive) and bound SP1/NC cleavage site residues 
P12-P12' (bronze ribbon |P12-P5|, red ribbon P4-P4'). 
mechanisms for these PRs, and will be important in the 
development of effective inhibitors for retroviruses 
that express PRs with either selected, or native, re-
sistance to active-site inhibitors. 
 
Materials and Methods 
 
Computational chemistry 
PR/ligand models were energy minimized prior to cal-
culation of interaction energy scores using Accelrys 
Discovery Studio (Dassault Systèmes, San Diego, CA) 
with parameters set to approximate in vitro conditions 
for direct interactions between proteins and ligands as 
previously described (Laco 2011, 2015). The only ex-
plicit water in the PR substrate/inhibitor models was a 
water tetrahedrally coordinated between either the HIV
-1 PR flaps Ile50 (A and B-subunits) backbone nitro-
gens, or structurally equivalent residues in the HIV-2/
SIV-cpz/SIV-sm/HTLV-1/EIAV/FIV PRs, and either 
the respective substrate residue P1 and P1’ backbone 
carbonyl oxygens or inhibitor oxygens, harmonic re-
straints were placed on those H-bonded heavy atoms 
as previously described (Laco 2015). The indicated 
structure coordinate files were used to build the respec-
tive PR substrate/inhibitor models: WT HIV-1 PR 
bound to the Gag SP1/NC cleavage site was based on 
1KJ7.pdb [19] with the addition of the HIV-1 PR 
HXB2 residues Val3 and Ser37 (Ratner et al. 1985), 
the 24-mer SP1/NC substrate backbone orientation 
served as the starting point for all PR/substrate models 
for consistency (Laco 2015). The MDR 3761 HIV-1 
PR mutations relative to WT HIV-1 PR [46] were built 
into 1KJ4.pdb [19] as previously described (Laco 
2015). HIV-1 substrates used in the in silico studies 
were based on the HIV-1 HXB2 strain (Ratner et al. 
1985). The EIAV PR (1FMB.pdb), FIV PR 
(2FIV.pdb), HTLV-1 PR (2B7F.pdb) were treated the 
same as HIV-1 PR (Gustchina et al. 1996, Kovalevsky 
et al. 2008, Laco et al. 1997, Li et al. 2005). HIV-2 PR 
was generated by mutating the SIV-sm PR, as de-
scribed herein, using the HIV-2 subtype A, isolate 
BEN, sequence (UniProtKB-P18096), uniprot.org 
(Consortium 2015). The SIV-cpz and SIV-sm PR 
models were generated by mutating the published SIV 
PR structure 1YTJ.pdb (Rose et al. 1996a) in Discov-
ery Studio to the amino acid sequences of the SIV-cpz 
MB66 isolate (UniProtKB-Q1A267) and the SIV-sm 
S4 F236 isolate (UnitProtKB-P12502) (D'Arc et al. 
2015), respectively, uniprot.org (Consortium 2015). 
The HTLV-1 PR was reverse engineered by either mu-
tating two S-groove residues (I85A/T88G) to give 
HTLV-1 2X PR, or the two S-groove residues (I85A/
T88G) and two active-site residues (V56I/A59I) to-
gether to give HTLV-1 4X PR. The default Discovery 
Studio orientations for the mutated HTLV-1 2X and 
4X PR side chains were used for the minimizations. 
Before starting the respective minimizations, the orien-
tations of HTLV-1 2X and 4X PRs native residues, 
and bound 24-mer substrate residues, were identical to 
the HTLV-1 PR and bound 24-mer substrate. 
 
HIV-1 Gag and Pol structure-based 3D models 
The HIV-1 full-length Gag polyprotein (MA/CA/SP1/
NC/SP2/p6) and Pol polyprotein (p6*/PR/RT/RH/IN) 
3D models were generated using published structures 
of Gag and Pol proteins (protein, PDB ID): MA-CA, 
1L6N.pdb (Tang et al. 2002); CA-SP1, 4XFX.pdb 
(Gres et al. 2015); NC, 1MFS.pdb (Lee et al. 1998); 
p6, 2C55.pdb (Fossen et al. 2005); PR monomer, 
1Q9P.pdb (Ishima et al. 2003); RT, 3T19.pdb (Gomez 
et al. 2011); IN, 4NYF.pdb (Wang et al. 2001), while 
the transframe encoded p6* structure was generated 
using the Robetta full-chain protein prediction server, 
http://robetta.bakerlab.org (Ovchinnikov et al. 2016). 
The proteins were bonded together using short random 
coil linkers containing missing residues, and then the 
structures were typed with the consistent force field 
(CFF) and energy minimized using implicit solvent 
and the same parameters in Discovery Studio as used 
above for HIV-1 PR (Laco 2015). Note: the relative 
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Figure 4. Schematic of HIV-1 Gag and Pol polyproteins and cleavage sites. Top row: interior vertical lines indicate cleav-
age sites; arrows indicate relative cleavage order from top to bottom for each polyprotein when cleaved in trans by HIV-1 PR 
(Pettit et al., 2005; Tritch et al., 1991). The length of the CA/SP1 (14-aa) and NC/SP2 (16-aa) cleavage sites C-terminal tails 
are indicated. The Gag-Pro-Pol polyprotein is composed of Gag with a TF region starting after NC that changes the reading 
frame to express p6* and the Pol polyprotein (not shown). 
orientations of the subdomains within the Gag and Pol 
polyproteins are in part for illustrative purposes as 
compared to the more extended orientations found 
within an immature HIV-1 virion (Bharat et al. 2014). 
 
Protein sequence alignments 
Protease 3D structures were aligned using 
PROMALS3D (Pei et al. 2008). The following pairs of 
viral Gag-Pro-Pol polyproteins were aligned using 
MUSCLE (Multiple Sequence Comparison by Log- 
Expectation, (Edgar 2004, McWilliam et al. 2015): 
HIV-1 (H2, group M, subtype B, isolate HXB2, Uni-
ProtKB-P04585) and SIV-cpz (isolate MB66, Uni-
ProtKB-Q1A267); and HIV-2 (subtype A, isolate 
BEN, UniProtKB-P18096 ) and SIV-sm (S4, isolate 
F236, UnitProtKB-P12502), uniprot.org (Consortium 
2015). 
 
Statistical analysis 
The GraphPad QuickCalcs t test calculator and paired t 
test were used for all statistical analyses (http://
www.graphpad.com/quickcalcs/ttest1.cfm). 
 
Results 
 
HIV-1 Gag/Pol cleavage site alignments, residues 
P12-P12' 
The HIV-1 PR is essential for virion maturation in the 
infected cell and for activation of the enzymes required 
to complete the viral replication cycle in the next host 
cell (Kohl et al. 1988, Le Grice et al. 1988). Both pro-
cesses require HIV-1 PR to cleave the ten primary 
Gag/Pol polyprotein cleavage sites in the correct order 
and rate, Figure 4.  
 How the HIV-1 PR accomplishes this is com-
plicated by the fact that the HIV-1 PR cleavage sites 
do not have a consensus sequence for residues P4-
P4’ (Pearl & Taylor 1987). As a result, substrate resi-
dues bound by the HIV-1 PR S-grooves (|P12-P5|) 
were included in an alignment and revealed that even 
for this expanded cleavage site alignment (P12-P12') 
there were still no residues at any position conserved 
in all ten cleavage sites, and for P10' there were no 
conserved residues, Figure 5. 
 However, there were two positions where 
there was conservation at four cleavage sites: P2, Asn 
(4X); and P1, Phe (4X), Figure 5. The HIV-1 PR like 
other retroviral PRs, including the FIV PR, can bind 
peptide substrates in either the N-to C-terminal, or C-
to N-terminal, orientation due to the structural sym-
metry of the PR dimer (Laco et al. 1997, Prabu-
Jeyabalan et al. 2002). When the Gag/Pol cleavage site 
residues P12-P1 were aligned C-to N-terminal (i.e., P1
-P12) with the respective P1’-P12’ residues Phe was 
found at |P1| in three additional cleavage sites for a 
total of 7X, and His was found at |P12| in two addition-
al cleavage sites for a total of 4X, followed by thirty-
four residues/positions where the conservation in-
creased by an additional cleavage site including at 
|P10| where six residues were conserved, Figure 5 yel-
low highlights. It was proposed that the heterogeneity 
of the Gag/Pol cleavage sites was due to the dual roles 
of the P12-P12’ residues: first as recognition sequenc-
es that regulated Gag/Pol polyprotein cleavage order; 
and second as structural components in the N-and C-
termini of the respective Gag/Pol cleavage products 
(Laco 2015), with the exception of the Gag derived 
SP1 and SP2 peptides, which are not part of any ma-
ture viral protein, Figure 4. 
 
WT HIV-1 PR in silico interaction with Gag/Pol 
cleavage sites 
The WT HIV-1 PR interactions with Gag/Pol cleavage 
sites were analyzed in silico using 8-mer and 24-mer 
peptide substrates in order to explore the role of the 
WT HIV-1 PR S-grooves in substrate recognition, Ta-
ble 1 (Laco 2015). This approach avoided the issues 
associated with in vitro peptide assays, which while 
having good kinetic resolution suffered from variable 
results (Billich et al. 1988, Kotler et al. 1988, 
Krausslich et al. 1989, Tozser et al. 1991). The WT 
HIV-1 PR in silico interaction energy scores with sub-
strates were compared to the in vitro cleavage of the 
Gag/Pol polyproteins. This was done to determine in 
silico which substrate length (8-mer/24-mer) best 
matched the published in vitro Gag/Pol cleavage order 
(Pettit et al. 2002, 2005). Previous results for WT HIV
-1 PR bound to the Gag MA/CA and SP1/NC sites 
(Laco 2015) were based on structures of HIV-1 PR 
with substrates from both HIV-1 NL4-3 and HXB2 
strains (King et al. 2012, Kozisek et al. 2007, Prabu-
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Figure 5. HIV-1 Gag/Pol cleavage site alignments P12-
P12’. HXB2 sequence, / indicates scissile bond. Residue 
conservation across all sites indicated as follows: bold, 2X; 
underlined, 3X; red, 4X. The Gag NC/SP2 and NC/TF 
cleavage sites have identical residues P12-P2'. The transla-
tional frame shift used to generate the Gag-Pro-Pol polypro-
tein occurs between the NC/TF cleavage site residues P2' 
and P3'. The transframe region contains p6* at the C-
terminus. Gray highlighted residues made electrostatic/H-
bond interactions with the MDR HIV-1 PR S-groove re-
sistance residue Thr73 (A/B subunits). P10' yellow high-
lighted residues were conserved when the P12-P1 residues 
were aligned C-to N-terminal (P1-P12) with the P1'-P12' 
residues (see Results, not shown). 
Jeyabalan et al. 2002, Wang et al. 2012). Here all sub-
strates used for in silico interaction energy scores were 
based on the HIV-1 HXB2 strain for consistency, Fig-
ure 5 (Ratner et al. 1985). The WT HIV-1 PR interac-
tion energy scores with nine Gag/Pol cleavage sites 
were reported alongside the published in vitro cleavage 
order for the same sites when part of Gag/Pol polypro-
teins, Table 1 (Pettit et al. 2002, 2005).  
 Notably, the scores for the MA/CA and SP1/
NC site 8-mers were out of order with the published in 
vitro cleaved Gag/Pol polyproteins, while the 24-mers 
were in order (excluding RT/RH and RH/IN sites, Ta-
ble 1). The RT/RH and RH/IN sites 8-mer and 24-mer 
scores were out of order due to being among the 
strongest interactions with WT HIV-1 PR (Table 1). 
Interestingly, the WT HIV-1 PR scores for the SP1/NC 
site went from one of the weaker 8-mer scores 
(incorrect order) to the strongest 24-mer score (correct 
order), Table 1. These results support the importance 
of the WT HIV-1 PR S-groove contacts with residues 
|P12-P5| in substrate recognition, Table 1 (Laco 2015). 
When the interaction energy scores between WT HIV-
1 PR and substrates were broken down for substrate 
residues |P12-P1| versus P4-P4’ it was found that four 
out of the nine cleavage site scores were weighted to-
wards the active-site/P4-P4'. The PR/RT site scores for 
substrate residues |P12-P1| and P4-P4' were evenly 
distributed between the S-grooves and active-site, Ta-
ble 1. 
 
MDR HIV-1 PR in silico interaction with Gag/Pol 
cleavage sites 
The evolution of HIV-1 PR multi-drug resistance typi-
cally begins with primary resistance mutations selected 
for in the active-site/flaps (i.e., Ile54Val and 
Asp30Asn), which reduces PR binding to inhibitors as 
well as Gag/Pol substrates (Laco 2015), resulting in 
inhibitor resistance along with reduced viral replicative 
capacity, Figure 1 Introduction. Next secondary re-
sistance mutations are selected for in the PR S-grooves 
(i.e., A71I and G73T) that increased interactions with 
substrate residues |P12-P5| (Laco 2015), and that re-
stored viral replicative capacity while maintaining in-
hibitor resistance, Figure 3 Introduction. The combina-
tion of HIV-1 PR primary and secondary resistance 
mutations resulted in multi-drug resistance and treat-
ment failure (Chen et al. 1995, Gulnik et al. 1995, 
Schock et al. 1996). 
Here the interactions between a MDR HIV-1 
PR, HIV-1 PR 3761 (Wang et al. 2012), which con-
tains seven resistance mutations including the S-
groove A71I and G73T mutations (Laco 2015), and 
nine HIV-1 Gag/Pol cleavage sites was analyzed in 
silico (Table 2). Like the WT HIV-1 PR (Table 1), the 
MDR HIV-1 PR interactions with the MA/CA and 
SP1/NC site 8-mers were out of order with the in vitro 
cleaved Gag/Pol polyproteins, while the respective 24-
mer scores were in order, Table 2. Similar to the WT 
HIV-1 PR, the MDR HIV-1 PR interactions with the 
RT/RH and RH/IN sites were the among the strongest 
making them out of order with the in vitro cleaved 
Gag/Pol polyproteins, Table 2. When the interactions 
between the MDR HIV-1 PR and substrates were bro-
ken down for substrate residues |P12-P5| and P4-P4’, it 
was found that for eight out of the nine cleavage sites 
the interaction between the MDR HIV-1 PR and sub-
strate was weighted towards the S-grooves and |P12-
P5|. Only the CA/SP1 site was weighted towards the 
active-site and P4-P4', Table 2. The MDR HIV-1 PR S
-groove secondary resistance residue Thr73 made di-
rect electrostatic/H-bond interactions with residues in 
all nine of the Gag/Pol cleavage sites, see Figure 5 
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  HIV-1 PR in vitro 
Cleavage rate (Order) 
HIV-1 PR in vitro 
(Cleavage Order) 
WT HIV-1 PR in silico  
Interaction energy 
24-mer Interaction 
Breakdown 
Cleavage Site Gag1 Gag-Pro-Pol2 8-mer 24-mer |P12-P5| P4-P4' 
MA/CA 10X↓(3) (2) -136 -248 -123 -125 
CA/SP1 400X↓(5) ND -125 -205 -90 -114 
SP1/NC 1 (1) (1) -122 -257 -141 -116 
NC/SP2 350X↓(4) ND -121 -245 -137 -108 
SP2/p6 9X↓(2) ND -120 -236 -123 -112 
P6*/PR   (4) -126 -226 -106 -120 
PR/RT   (5) -123 -224 -112 -112 
RT/RH   (3) -139* -255* -125 -130 
RH/IN   (2) -129* -254* -133 -121 
Table 1. WT HIV-1 PR interaction energy scores for Gag/Pol substrates. 
WT HIV-1 PR interaction energy in kcal/mol for Gag and Pol cleavage sites as 8-mers and 24-mers, with a breakdown of the 
24-mer substrates scores for |P12-P5| and P4-P4' (strongest interactions underlined). 1,2 The in silico interaction energy scores 
were compared to the published in vitro cleavage orders for the same sites in the context of Gag and Gag-Pro-Pol polyproteins 
where Gag-Pro-Pol contained an inactive PR with active HIV-1 PR supplied in trans (Pettit et al., 2002; Pettit et al., 2005). 
*The 3D context of RT/RH and RH/IN sites were examined in Results. 
gray highlighted residues. 
 Interestingly, two incongruous results stand 
out in Tables 1 and 2. The first is the magnitude of 
difference in the in vitro cleavage rates reported for the 
CA/SP1 site (400-fold lower) and NC/SP2 site (350-
fold lower) relative to the SP1/NC site when part of a 
Gag polyprotein (Pettit et al. 2002), and the 0.04 to 
0.20-fold difference for the WT and MDR HIV-1 PRs 
in silico interaction energy scores for the CA/SP1 and 
NC/SP2 sites 24-mers relative to the SP1/NC site 24-
mer (Tables 1 and 2). One explanation is that due to 
earlier cleavages at the SP1/NC and SP2/p6 sites, the 
CA/SP1 and NC/SP2 sites only had 14 and 16 resi-
dues, respectively, that extended past the C-terminal 
side of the scissile bond, Figure 4. This is in contrast to 
all other Gag/Pol cleavage sites that were stabilized by 
structured domains on both sides of the scissile bond, 
Figure 4. The orientations of the CA/SP1 and NC/SP2 
site C-terminal tails could hinder HIV-1 PR binding to 
the respective cleavage site residues P1’-P12’ in vitro, 
while in silico those potential issues were not taken 
into account. Complicating the issue is that the context 
of those sites within the Gag polyprotein could not be 
analyzed due to the lack of a full-length Gag structure. 
The second incongruous result from Tables 1 and 2 is 
that while the RT/RH and RH/IN sites were cleaved 
slower in vitro than the SP1/NC site in the respective 
Gag/Pol polyproteins, the RT/RH and RH/IN 24-mer 
substrates had some of the strongest in silico interac-
tions with both the WT and MDR HIV-1 PRs (Tables 
1 and 2). However, no obvious explanation could be 
proposed based on either the position of the cleavage 
sites in the Pol polyprotein, or the primary sequence of 
the cleavage sites, Figure 4 and 5. As a result, attention 
was turned to the 3D context of both the Gag CA/SP1 
and NC/SP2 sites, and the Pol RT/RH and RH/IN sites. 
However, while the structures for nearly all of the ma-
ture proteins from the HIV-1 Gag/Pol polyproteins 
have been solved using crystallography and NMR, to 
our knowledge no full-length structure-based energy 
minimized 3D models of the HIV-1 Gag and Pol poly-
proteins have been published. 
 
HIV-1 Gag and Pol polyprotein 3D models 
HIV-1 Gag and Pol polyprotein 3D models were built 
in silico using published structures of Gag and Pol de-
rived proteins, while the p6* protein structure was gen-
erated using the Robetta full-chain protein prediction 
server, Materials and methods (Ovchinnikov et al. 
2016). The individual proteins were connected as re-
quired with random coil linkers containing missing 
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HIV-1 PR in vitro 
Cleavage rate (Order) 
HIV-1 PR in vitro 
Cleavage (Order) 
MDR HIV-1 PR in  silico 
Interaction energy 
24-mer Interaction 
Breakdown 
Cleavage Site Gag1 Gag-Pro-Pol2 8-mer 24-mer 
|P12-
P5| 
P4-P4' 
MA/CA 10X↓(3) (2) -126 -248 -132 -116 
CA/SP1 400X↓(5) ND -115 -205 -101 -104 
SP1/NC 1(1) (1) -117 -254 -147 -107 
NC/SP2 350X↓(4) ND -110 -246 -144 -102 
SP2/p6 9X↓(2) ND -116 -237 -127 -110 
P6*/PR   (4) -117 -244 -131 -113 
PR/RT   (5) -117 -224 -127 -97 
RT/RH   (3) -129* -259* -136 -123 
RH/IN   (2) -120* -256* -146 -110 
Table 2. MDR HIV-1 PR interaction energy scores for Gag/Pol substrates. 
Figure 6. HIV-1 Gag polyprotein 3D model. Protein back-
bone as a ribbon, individual subdomains in blue with black 
labels, cleavage site backbone for residues |P12-P5| in 
bronze, P4-P4' in red. Cleavage site labels in red with resi-
dues P1/P1' shown: carbon, grey; oxygen, red; nitrogen, 
blue; sulfur, yellow. The overlapping portions of the CA/
SP1 and SP1/NC, and NC/SP2 and SP2/p6, cleavage sites 
are green, Fig. 4 and 5. The overall orientation was influ-
enced by illustrative considerations and in not meant to rep-
resent the more extended orientation within an immature 
virion. 
MDR HIV-1 PR interaction energy in kcal/mol for Gag and Pol cleavage sites as 8-mers and 24-mers, with a breakdown of the 
24-mer substrates scores for |P12-P5| and P4-P4' (strongest interactions underlined). 1,2 The in silico interaction energy scores 
were compared to the published in vitro cleavage orders for the same sites in the context of Gag and Gag-Pro-Pol polyproteins 
where Gag-Pro-Pol contained an inactive PR with active HIV-1 PR supplied in trans (Pettit et al., 2002; Pettit et al., 2005). 
*The 3D context of the RT/RH and RH/IN sites were examined in Results. 
residues to generate a full-length Gag polyprotein and 
Pol polyprotein with an N-terminal p6*, Figure 6 and 
7. The Gag polyprotein 3D model revealed that all five 
cleavage site residues P12-P12’ were solvent exposed 
in extended random coil configurations, Figure 6. As a 
result, the dramatically reduced in vitro cleavage rates 
for the CA/SP1 and NC/SP2 sites were likely due sole-
ly to the short C-terminal tails, Figure 4. Those C-
terminal tails could be either disordered random coils, 
or form α-helices (Bharat et al. 2014), and in either 
case interfere with HIV-1 PR binding and cleavage 
(Table 1). This may explain why the Gag NC/SP2 24-
mer scores for both the WT and MDR PRs were 
stronger than expected based on the in vitro Gag cleav-
age order, in that the high affinity primary sequence 
may be used to off-set the weaker in vitro binding of 
the PRs to the short C-terminal tail of the NC/SP2 
cleavage site (Tables 1 and 2, Figure 4). 
 Compared to the Gag cleavage sites, the Pol 
cleavage sites were not as solvent accessible: the p6*/
PR site residues P12-P8, and PR/RT site residues P12-
P9, were part of α-helices, however, those structured 
residues likely contributed only a minor steric hin-
drance to HIV-1 PR binding since the remaining cleav-
age site residues were solvent exposed, Figure 7. In 
contrast, the Pol RT/RH site residues P12-P12’ made 
extensive β-sheet contacts with the RNase H domain, 
while the RH/IN site residues P12-P6 and P3’-P12’ 
were both part of α-helices that made interactions with 
RNase H β-sheets and integrase α-helices, respective-
ly, Fig 7. Those finding explain why the Pol RT/RH 
and RH/IN site 24-mers (P12-P12’) had some of the 
strongest in silico interactions with WT and MDR HIV
-1 PRs (Tables 1 and 2), while in vitro they were re-
ported to be the third and second fastest cleaved sites 
respectively, in that the high affinity primary sequence 
of the cleavage sites likely enhanced PR binding to the 
sites in the context of the Pol polyprotein, Figure 7. 
The results in Tables 1 and 2 indicated that the in silico 
interaction energy scores between both WT and MDR 
HIV-1 PRs and the 24-mer Gag/Pol cleavage sites 
(P12-P12’) in general reflected the published in vitro 
cleavage order for sites that were in predominantly 
solvent exposed regions of the polyproteins, Ta-
bles 1 and 2. In contrast, the WT and MDR HIV-1 
PRs in silico scores with the Gag/Pol cleavage site 
residues P4-P4’ (8-mers) were more out of order 
with the reported in vitro cleavage orders and had 
lower resolution between the scores for the fast 
SP1/NC site and the slower CA/SP1, p6*/PR, and PR/
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Figure 7. HIV-1 Pol polyprotein 3D model. Protein back-
bone as a ribbon, individual subdomains in blue with black 
labels, except for the RNaseH domain in teal. Cleavage site 
backbone for residues |P12-P5| in bronze, P4-P4' in red. 
Cleavage site labels in red with residues P1/P1' shown: car-
bon, grey; oxygen, red; nitrogen, blue. The overall orienta-
tion was influenced by illustrative considerations and is not 
meant to represent the more extended orientation within an 
immature virion. 
Figure 8. Structure-based HIV and SIV protease alignments. Top, HIV-1 PR/SIV-cpz PR; bottom, HIV-2 PR/SIV-sm PR 
with HIV-1 PR included as a resistance residue reference. Gray highlighted residues indicate amino acid identity between 
aligned PRs. HIV-1 PR residues that when mutated contributed to inhibitor resistance in bold, primary resistance residues indi-
cated by underlined numbers, HIV-2 PR and SIV PR native resistance residues in bold. Active-site Asp25 (D25) italicized. 
Potential resistance residues in HIV-2 and SIV-sm at position 20 underlined. 
  
RT sites, Tables 1 and 2. 
 
Evolution of HIV-1 and HIV-2 from SIV: Structure
-based PR alignments 
The evolution of HIV-1 PR multi-drug resistance to 
active-site inhibitors results in treatment failure 
(Brown et al. 2003, Mocroft et al. 2003, Richman et 
al. 2004, Rosenbloom et al. 2012). This could repre-
sent a novel evolutionary pathway for HIV-1 PR inhib-
itor resistance. Alternatively, it could be a common 
pathway used by all retroviral proteases to adapt, dur-
ing cross-species transmissions (Wolfe et al. 2005), to 
mutations in Gag/Pol cleavage sites selected for in the 
non-native host. Mutation of the Gag/Pol cleavage 
sites also occurs during HIV-1 adaptation to a new na-
tive host due to cytotoxic T lymphocyte (CTL) selec-
tive pressure on viral proteins including Gag/Pol and 
the respective cleavage sites (Phillips et al. 1991, 
Prince et al. 2012, Seibert et al. 1995). It is important 
to note that the HIV-1 ancestral SIV was from chim-
panzees/SIV-cpz (Gao et al. 1999, Santiago et al. 
2002), while the HIV- 2 ancestral SIV was from sooty 
mangabeys/SIV-sm (Lemey et al. 2003), since the 
amino acid sequences differ for both PRs, Figure 8. 
The SIV-cpz and SIV-sm PRs share 57% identity, Fig-
ure 8. It has been reported that both SIV-sm PR and 
HIV-2 PR had native resistance to clinical HIV-1 PR 
inhibitors: SIV-sm, amprenavir; HIV-2, amprenavir, 
atazanavir, nelfinavir, ritonavir, and tipranavir (Brower 
et al. 2008, Desbois et al. 2008, Rodes et al. 2006, 
Witvrouw et al. 2004). The 3D structures for HIV-1 
and SIV-cpz PRs, and HIV-2 and SIV-sm PRs, were 
aligned to determine whether the PRs contained known 
HIV-1 PR resistance residues, Figure 8. HIV-1 PR had 
83% identity with the SIV-cpz PR that had one native 
resistance residue (Val10), Figure 8. HIV-2 PR had 
85% identity with the SIV-sm PR, with HIV-2 PR hav-
ing seven native resistance residues while SIV-sm PR 
had six native resistance residues, Figure 8. The HIV-
2, SIV-cpz, and SIV-sm PRs native resistance residues 
when found in HIV-1 PR at the same 3D position con-
tributed to primary and secondary inhibitor resistance, 
http://hivdb.stanford.edu (Rhee et al. 2003, Wensing et 
al. 2015). When the HIV-2 PR and both SIV PRs were 
analyzed for the presence of S-grooves, all three PRs 
were found to have S-grooves similar to HIV-1 PR and 
HTLV-1 PR, Figure 3 and 10 (Laco 2015). 
 
Evolution of HIV-1 and HIV-2 from SIV: Gag/Pol 
cleavage site alignments 
While HIV-2 and SIV PRs were shown to contain na-
tive resistance residues, neither of those viruses had 
been exposed to HIV-1 PR active-site inhibitors during 
evolution, Figure 8. As a result, we explored how the 
HIV-1 and HIV-2 Gag/Pol cleavage sites evolved from 
the respective SIV Gag/Pol cleavage sites, during ad-
aptation to the human host, to see how that may have 
contributed to the native resistance residues in the PRs. 
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Figure 9. HIV and SIV Gag/Pol cleavage site alignments. Cleavage site residues P12-P12' shown, gray highlighted residues 
indicate identity between aligned sequences. For each cleavage site: top, HIV-1/SIV-cpz; bottom, HIV-2/SIV-sm. Percent iden-
tity for P4-P4' shown above cleavage site scissile bond (/); combined percent identity for |P12-P5| shown on the right side 
above P12'. *The p6*/PR cleave site percent identities were calculated separately for Gag (P12-P4 and P4-P1, left value) and 
Pol (P1'-P4' and P4'-P12', right value). 
The HIV-1 and HIV-2 Gag/Pol cleavage site residues 
(P12-P12’) were aligned with the respective cleavage 
sites from the nearest ancestral SIV based on gag gene 
sequences, Figure 9 (D'Arc et al. 2015). The HIV-1 
and HIV-2 cleavage site residues were divided into 
two groups (|P12-P5| and P4-P4’) with the percent 
identity to the respective SIV cleavage sites indicated 
on the right side for |P12-P5|, and above the scissile 
bond for P4-P4', Figure 9. Note that the p6*/PR site 
residues P12-P1 were grouped with the Gag cleavage 
sites, while the residues P1'-P12' were grouped with 
the Pol cleave sites. HIV-1 had similar identity as HIV
-2 with all of the respective SIV Gag cleavage site resi-
dues P4-P4' and p6*/PR residues P4-P1 (two-tailed P 
value = 0.1087), Figure 9. In contrast, HIV-2 had sig-
nificantly more identity with the SIV-sm Gag cleavage 
site residues |P12-P5|, than did HIV-1 with the respec-
tive SIV-cpz cleavage site residues |P12-P5| (two-
tailed P value = 0.0090), Figure 9. The HIV-1 and HIV
-2 Pol cleavage site residues P12-P12' were overall 
highly conserved with the respective SIV Pol cleavage 
sites, Figure 9. These results indicated that HIV-2 had 
greater identity with SIV-sm Gag cleavage sites than 
did HIV-1 with SIV-cpz Gag sites, and the HIV-2 Gag 
cleavage site identities were more evenly distributed 
across cleavage site residues P12-P12’, Figure 9. Mu-
tation of the solvent accessible Gag cleavage sites, dur-
ing viral adaptation to the human host, may have been 
one of the factors that drove the evolution of HIV-1 
PR to weight substrate interactions towards the active-
site and more conserved Gag cleavage site residues P4-
P4’, versus the S-grooves and divergent Gag cleavage 
site residues |P12-P5|, Figure 9. 
 
Distribution of PR interactions with 24-mer sub-
strates in silico 
Based on the analysis of the HIV-1 and HIV-2 Gag/Pol 
cleavage site evolution from the respective SIVs the 
following hypothesis was proposed: due to CTL selec-
tive pressure in the human host (Phillips et al. 1991, 
Prince et al. 2012, Seibert et al. 1995), HIV-1 cleavage 
sites had more residues conserved P4-P4’ versus |P12-
P5| from SIV-cpz and this drove selection of an HIV-1 
PR that had stronger active-site interactions with sub-
strate residues P4-P4’. At the same time, HIV-1 PR S-
groove interactions with substrate residues |P12-P5| 
were weakened in order to: 1) balance HIV-1 PR affin-
ity for substrates to maintain the overall Gag/Pol poly-
protein cleavage order required for virion maturation, 
Table 1; and 2) prevent premature activation of HIV-1 
PR during formation of the immature virion (Strickler 
et al. 1989). One consequence was that HIV-1 PR be-
came sensitive to active-site inhibitors. In contrast, 
during HIV-2 adaptation to the human host the Gag/
Pol cleavage sites had a more balanced and higher con-
servation of SIV-sm cleavage site residues |P12-P5| 
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HIV-1 MDR HIV-1 HIV-2 SIV-cpz SIV-sm HTLV-1 EIAV FIV 
-123/-125 -132/-116 -120/-115 -135/-111 -127/-114 -128/-107 -152/-120 -130/-110 
Table 3. Protease interaction energy scores with MA/CA 24-mer residues |P12-P5| and P4-P4'. 
HIV-1, MDR HIV-1, HIV-2, SIV-cpz, SIV-sm, HTLV-1, EIAV, FIV PRs interaction energy scores (kcal/mol) with the corre-
sponding MA/CA substrate residues |P12-P5| and P4-P4'. 
Figure 10. HTLV-1 PR with bound MA/CA 24-mer substrate. A) Front view with flaps on top, A and B subunits as back-
bone ribbons, active-site mutation D32N center (A and B subunits). Atom colors: oxygen, red; nitrogen, blue; carbon, grey. 
Tetrahedrally coordinated water with all atoms blue (center, above substrate). Back mutated residues shown starting clockwise 
bottom left: S-groove I85A and T88G carbons in bronze; active-site V56I and A59I carbons in red. Gag MA/CA substrate 
backbone |P12-P5| in red; P4-P4' in bronze. B) Side view of A (left subunit) showing the anti-parallel beta sheet with one rib-
bon colored green starting at the tip of the flap and ending at the bottom of the S-groove, with the other strand of the anti-
parallel beta sheet below as a blue ribbon. 
Figure 9, while HIV-2 PR also acquired the secondary 
resistance residue Ala73, Figure 8. That mutation 
could help stabilize HIV-2 PR S-groove interactions 
with cleavage site residues |P12-P5| and along with the 
inherited S-groove secondary resistance residue Val71 
may have contributed to HIV-2 PR weighting interac-
tions with Gag/Pol cleavage sites more towards the S-
grooves and cleavage site residues |P12-P5|. This in 
turn would allow HIV-2 Gag/Pol substrates to out-
compete the binding of active-site inhibitors to HIV-2 
PR. In order to test this hypothesis, the interaction en-
ergy scores between HIV-2, SIV-cpz, and SIV-sm PRs 
and the respective MA/CA 24-mer substrates were cal-
culated for |P12-P5| and P4-P4’. WT HIV-1 PR inter-
action with the MA/CA substrate was weighted to-
wards the active-site and residues P4-P4', while the 
HIV-2, SIV-cpz, and SIV-sm PRs interactions with the 
respective MA/CA substrates were all weighted to-
wards the S-grooves and MA/CA substrate residues 
|P12-P5|, Table 3. The weighting of the HIV-2, SIV-
cpz, and SIV-sm PRs interactions towards the S-
grooves and substrate residues |P12-P5| correlated with 
resistance to active-site inhibitors. These findings sup-
port the hypothesis that PR/substrate interactions dom-
inated by S-groove binding to cleavage site residues 
|P12-P5| allows Gag/Pol polyprotein cleavage sites to 
out-compete the binding of active-site inhibitors to PR 
(Laco 2015). 
 
In silico analysis of HTLV-1 PR native multi-drug 
resistance 
In contrast to the native primary resistance of HIV-2 
and SIV-sm PRs (Results), the HTLV-1 PR has native 
multi-drug resistance to HIV-1 PR clinical inhibitors 
(Louis et al. 1999, Pettit et al. 1998), and contains a 
total of ten native primary/secondary resistance muta-
tions (Laco 2015, Li et al. 2005). HTLV-1 PR has 
been reported to have an S-groove residue that in silico 
made direct H-bond interactions with substrate resi-
dues |P12-P5| (Laco 2015). That HTLV-1 PR S-groove 
residue (Thr88) aligned in 3D with the WT HIV-1 PR 
Gly73 that when mutated contributed to HIV-1 PR 
inhibitor resistance (Laco 2015). Here we tested 
whether HTLV-1 PR could be reverse engineered in 
silico, in a way opposite to how HIV-1 PR evolved 
into a MDR HIV-1 PR, to make the HTLV-1 PR inhib-
itor sensitive while maintaining interactions with sub-
strates. HTLV-1 PR S-groove residues Ile85 and 
Thr88, equivalent to the HIV-1 PR secondary re-
sistance mutations Ala70Ile and Gly73Thr (Rhee et al. 
2003, Wensing et al. 2015), contributed to interactions 
with substrate residues |P12-P5|, Table 4 (Laco 2015). 
Here those S-groove residues were back mutated to 
equivalent residues found in WT HIV-1 PR to give the 
HTLV-1 2X PR (Ile85Ala and Thr88Gly), Figure 10.  
The interaction between HTLV-1 2X PR and 
the MA/CA 24-mer substrate decreased by 4.9 kcal/
mol consistent with a loss of S-groove contacts to sub-
strate residues |P12-P5|, Table 4. Next, the HTLV-1 
PR active-site residues Val56 and Ala59, equivalent to 
HIV-1 PR Ile47Val and Ile50Ala primary resistance 
mutations, were back mutated to Val56Ile and 
Ala59Ile and along with the S-groove mutations 
Ile85Ala and Thr88Gly resulted in the HTLV-1 4X 
PR, Figure 10. The HTLV-1 4X PR had a 2.6 kcal/mol 
stronger interaction with indinavir while restoring in-
teractions with the MA/CA 24-mer substrate to a level 
similar to that for the native HTLV-1 PR, Table 4. In-
terestingly, when the interaction energy scores were 
broken down for the HTLV-1 4X PR and the MA/CA 
24-mer substrate, the interactions were still found to be 
weighted towards the S-grooves and |P12-P5|, Table 4. 
 Since the HTLV-1 4X PR S-groove interactions with 
substrate residues |P12-P5| were still the dominant in-
teraction with the MA-CA substrate the potential exists 
in vitro for the MA/CA cleavage site, in the context of 
the Gag polyprotein, to out-compete active-site inhibi-
tor binding to the HTLV-1 4X PR. These results indi-
cate the potential complexity of reverse engineering 
the HTLV-1 PR into an inhibitor sensitive PR. It is 
interesting to note that by acquiring the bulky active-
site mutations Val56Ile/Ala59Ile, the HTLV-1 4X PR 
flaps had to move away from the substrate residues P4-
P4' in order to accommodate them. That flap move-
ment was then translated to the S-grooves via the anti-
parallel beta-sheets that connect the flaps and S-
grooves and increased interactions with substrate resi-
dues |P12-P5|, Figure 10 B and 11. The HIV-1 PR and 
all other retroviral PRs studied here have similar anti-
parallel beta-sheets connecting the flaps and S-
grooves, Figure 3 B. 
 
Non-primate retroviral PRs with native multi-drug 
resistance 
In order to extend the native resistance findings for the 
HIV-2 and HTLV-1 PRs, non-primate retroviruses 
were next examined. EIAV and FIV have both been 
reported to encode native MDR PRs (Kervinen et al. 
1998), with structures published for both (Kervinen et 
al. 1998, Laco et al. 1997). Structure based alignment 
of EIAV and FIV PRs with HIV-1 PR revealed that 
they had 28% and 24% identity with HIV-1 PR, re-
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   HTLV-1 PR  HTLV-1 2X PR (S-groove) HTLV-1 4X PR (S-groove/AC) 
MA/CA 24-mer 
-235.9 (128.6/-
107.2) 
-231.0 (-123.7/-107.3) -235.6 (-126.4/-109.2)   
Indinavir -84.1 -84.8 -86.7   
Table 4. HTLV-1 PRs interaction energy scores with MA/CA 24-mer and indinavir. 
HTLV-1 PR and mutant HTLV-1 PRs interaction energy scores (kcal/mol) with MA/CA 24-mer substrate residues: P12-P12'; 
|P12-P5|; P4-P4'. Bottom, scores for the same PRs and the active-site inhibitor indinavir. 
spectively, Figure 12. When both PRs were analyzed 
for native resistance residues, EIAV and FIV PRs were 
found to each have six residues that when found at the 
same 3D position in HIV-1 PR contributed to primary 
and secondary inhibitor resistance, and included S-
groove residues, Figure 12 (Rhee et al. 2003, Wensing 
et al. 2015).  
 In the structure of an unliganded MDR HIV-1 
PR the flaps were in an open conformation (Yedidi et 
al. 2014), as was the case for two MDR HIV-1 PRs 
with bound inhibitor (Liu et al. 2013a, b). In contrast, 
the structure of an unliganded WT HIV-1 PR had the 
flaps in a closed conformation (Wlodawer et al. 1989). 
These published structures demonstrated that the ori-
entation of the flaps correlated with the sensitivity of 
the respective PRs to active-site inhibitors. Here inhib-
itor-resistant PRs were shown to have weaker interac-
tions between the flaps/active-site and substrate resi-
dues P4-P4’, which was compensated for by stronger 
interactions between the S-grooves and substrate resi-
dues |P12-P5|, including the MDR HIV-1, HIV-2, SIV-
sm, HTLV-1, EIAV, and FIV PRs (Table 3). 
 In addition, like HTLV-1 PR, EIAV and FIV 
PRs had a number of residues that were found at re-
sistance positions in HIV-1 PR, though had not been 
reported as resistance residues for HIV-1 PR (Rhee et 
al. 2003, Wensing et al. 2015). For example, HIV-1 
PR Asp30 H-bonds to nelfinavir stabilizing the interac-
tion between WT HIV-1 PR and nelfinavir, while the 
Asp30Asn mutation results in the loss of that H-bond 
making the mutant HIV-1 PR resistant to nelfinavir 
(Kolli et al. 2014). The EIAV PR Thr30 aligns with 
HIV-1 PR Asp30; it is likely that the shorter Thr30 
side chain also does not H-bond to nelfinavir and so 
explains EIAV PR resistance to nelfinavir, Figure 12 
(Kervinen et al. 1998). Likewise, the HIV-1 PR Gly48 
when mutated to Val contributed to saquinavir re-
sistance due to the loss of a stabilizing H-bond be-
tween the HIV-1 PR Gly48Val backbone carbonyl ox-
ygen and saquinavir (Liu et al. 2008). Interestingly, the 
FIV PR Ile57 was found at the equivalent 3D position 
to HIV-1 PR Gly48 and so may play a similar role as 
the HIV-1 PR Gly48Val mutation in FIV PR resistance 
to saquinavir (i.e., RO31-8959), Figure 12 (Lin et al. 
2000). Next the interaction energy scores were calcu-
lated for EIAV PR and FIV PR bound to the respective 
MA/CA 24-mer substrates. The EIAV and FIV PRs 
interaction with the respective MA/CA substrates were 
also weighted towards the S-grooves and substrate res-
idues |P12-P5|, versus the active-site and residues P4-
P4’ (Table 3). Given that EIAV and FIV have been 
estimated to be in the respective hosts for millions of 
years (Cook et al. 2013, Pecon-Slattery et al. 2008), 
these findings suggest that there could be an evolution-
ary trend for retroviral PRs to weight substrate interac-
tions towards the S-grooves and substrate residues 
|P12-P5| with one consequence being native resistance 
to active-site inhibitors. 
 
Discussion 
 
We have shown that the WT HIV-1 PR and MDR HIV
-1 PR in silico interactions with solvent exposed Gag/
Pol 24-mer cleavage sites correlated better with the 
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Figure 11. Reverse Engineered HTLV-1 PRs interaction with MA/CA 24-mer on a per residue basis. The reverse engi-
neered HTLV-1 2X PR and 4X PR interaction energy scores, on a per residue basis, with the MA/CA substrate residues P12-
P12’ (kcal/mol). Scores relative to the native HTLV-1 PR residue interaction energy scores that were set to zero. 
reported in vitro cleavage order than did the respective 
8-mers, Tables 1 and 2. This demonstrated the im-
portance of the HIV-1 PRs S-groove interactions with 
substrate residues |P12-P5| in determining the Gag/Pol 
cleavage order. At the same time, WT HIV-1 PR 
weighted the interaction with the 24-mer substrates 
towards the active-site and residues P4-P4’ for four 
cleavage sites and the S-groove and |P12-P5| for four 
cleavage sites, while the the PR/RT site was equally 
weighted between the S-grooves and active-site (Table 
1). The Gag/Pol cleavage sites in which the WT HIV-1 
PR interactions with substrates were weighted towards 
the active-site/P4-P4’ (MA/CA, CA/SP1, p6*/PR, RT/
RH) may be responsible for the inhibitor sensitivity of 
the WT HIV-1 PR, due to active-site inhibitors being 
able to outcompete those substrates for binding to WT 
HIV-1 PR (Table 1). In contrast, the MDR HIV-1 PR 
interactions with 24-mer substrates were weighted to-
wards the S-grooves and residues |P12-P5| for eight 
out of the nine Gag/Pol cleavage sites, which may be 
responsible for allowing the Gag/Pol substrates to out-
compete inhibitor binding to the MDR HIV-1 PR ac-
tive-site (Table 2), and correlates with the high level 
resistance of the MDR HIV-1 PR to active-site inhibi-
tors (Wang et al. 2012). The only 24-mer cleavage site 
where the MDR HIV-1 PR interactions were weighted 
towards P4-P4’ was the Gag CA/SP1 site, the slowest 
cleaved site in vitro, Table 2. Inhibition of cleavage at 
the CA/SP1 site would still allow virion maturation to 
proceed under optimal inhibitor levels and in the pro-
cess release more active PR shifting the inhibitor/PR 
ratio towards PR. These results are supported by a 
published in vitro MDR HIV-1 PR cleavage assay that 
used a peptide substrate, that does not bind to the PR S
-grooves, and resulted in a relative 8.4-fold weaker in 
vitro activity for the MDR HIV-1 PR as compared to 
cleavage at the SP1/NC site in full-length Gag (Laco 
2015). This suggests that MDR HIV-1 PR inhibitor 
resistance may be significantly underestimated in vitro 
when short peptide substrates are used due to the weak 
binding of the MDR HIV-1 PR to substrate residues P4
-P4’ (Table 2). In contrast, the published in vitro re-
sults for the WT HIV-1 PR using the same peptide 
substrate and full-length Gag demonstrated that the 
WT HIV-1 PR had only a relative 2-fold weaker in 
vitro activity for the peptide versus Gag because the 
WT HIV-1 PR was more focused on flap/active-site 
interactions with substrate residues P4-P4', Table 1 
(Laco 2015). This suggests that the sensitivity of WT 
HIV-1 PR to active-site inhibitors may be modestly 
overestimated in vitro when short peptide substrates 
are used. 
 Next we examined whether the inhibitor re-
sistance residues selected for in the MDR HIV-1 PR, 
including primary active-site mutations and secondary 
S-groove mutations, were found in closely related ret-
roviruses that had not been exposed to protease inhibi-
tors (Results). This was done in order to determine if 
the MDR HIV-1 PR resistance evolution was either a 
novel pathway used solely for inhibitor resistance, or a 
pathway common to all retroviral proteases in order to 
adapt to mutated Gag/Pol substrates selected to escape 
in vivo CTL detection (Phillips et al. 1991, Prince et 
al. 2012, Seibert et al. 1995). When the HIV-1 and 
HIV-2 PRs were aligned with the evolutionary closest 
SIV PRs, HIV-1 PR was found to have lost the one 
native resistance residue found in SIV-cpz PR, while 
HIV-2 PR gained one native resistance residue in addi-
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Figure 12. Structure-based alignment of HIV-1 PR with EIAV and FIV PRs. Gray highlighted residues indicate identity 
between aligned sequences. HIV-1 PR residues that when mutated contributed to inhibitor resistance in bold, positions of pri-
mary resistance residue indicated by underlined numbers, EIAV and FIV PRs native resistance residues in bold, underlined 
EIAV and FIV residues indicate potential native resistance residues. HIV-1 PR active-site Asp25 (D25) italicized, as are the 
active-site residues for EIAV (D25) and FIV (D30). 
tion to inheriting the six native resistance residues pre-
sent in SIV-sm PR, Figure 8. Since neither HIV-1, nor 
HIV-2, evolved from the respective SIV in the pres-
ence of protease inhibitors, the evolution of the corre-
sponding Gag/Pol substrates were examined to see 
how they could explain the resistance residue inher-
itance pattern of HIV-1 and HIV-2 PRs, Figure 9. The 
HIV-1 Gag/Pol cleavage sites had a significant loss in 
identity with the respective SIV-cpz Gag/Pol cleavage 
site residues |P12-P5|, and this may have contributed to 
the WT HIV-1 PR weighting interactions towards the 
flaps/active-site and the conserved cleavage site resi-
dues P4-P4', Figure 9 and Table 1. The HIV-1 PR fo-
cus on substrate residues P4-P4' correlated with HIV-1 
PR losing the SIV-cpz PR Val10 native resistance resi-
due since Val10 is also the P10' residue in the p6*/PR 
cleavage site and would be bound in the S-grooves, 
Figure 3 and 5. In contrast, the HIV-2 Gag/Pol cleav-
age sites overall retained significantly more identity 
with the SIV-sm cleavage sites, and non-conserved 
residues in the HIV-2 Gag/Pol cleavage sites were 
more evenly distributed across cleavage site residues 
P12-P12', Figure 9. The net result was the evolution of 
an HIV-2 PR that weighted S-groove interactions to-
wards substrate residues |P12-P5| due in part to the 
acquisition of the native S-groove secondary resistance 
residue Ala73. And so during adaptation to the human 
host, the HIV-1 PR focused more on substrate residues 
P4-P4' and became acutely sensitive to active-site in-
hibitors (Rhee et al. 2003, Wensing et al. 2015). In 
contrast, the HIV-2 PR weighted S-groove interactions 
towards substrate residues |P12-P5| as shown for the 
MA/CA site (Table 3) resulting in native resistance to 
many HIV-1 PR active-site inhibitors, Results. These 
findings support the hypothesis that HIV-1 PR used a 
common retroviral PR pathway to acquire multi-drug 
resistance. As a result, HIV-1 PR active-site inhibitors 
can drive the evolution of HIV-1 PR resistance as well 
as select for adaptive mutations in the Gag/Pol cleav-
age sites (McKinnon et al. 2011). Transmission of the 
resulting MDR HIV-1 eliminates PR active-site inhibi-
tors as a treatment option. By targeting the HIV-1 PR 
S-grooves, along with the active-site, the potential loss 
of PR active-site inhibitors could be avoided. This ap-
proach may be critical given that in 2012 of the esti-
mated 1.5 million HIV-1 infected individuals in the 
United States and Puerto Rico only 30% had the virus 
suppressed to < 200 copies/mL (Frieden et al. 2015). 
Likewise, the HIV-2, HTLV-1, EIAV, and FIV PRs, 
which all contain S-groove resistance residues, could 
be targeted with both S-groove inhibitors and active-
site inhibitors in order to prevent the evolution of PRs 
that re-weighted substrate interactions towards P4-P4' 
in order to escape S-groove inhibitors. 
 The HIV-1 Gag and Pol polyprotein 3D mod-
els revealed the solvent accessibility of the Gag cleav-
age site residues versus several solvent inaccessible 
Pol cleavage sites (i.e., RT/RH and RH/IN), Figure 6 
and 7. In the cell, soluble proteases degrade cytosolic 
proteins at low levels to release approximately ten resi-
due long peptides that are then bound by MHC class I 
receptors for presentation on the cell surface for CTL 
surveillance (Kourjian et al. 2014, Lazaro et al. 2015, 
Yewdell et al. 1999, Zervoudi et al. 2013). Due to the 
solvent accessibility of the Gag cleavage sites, they 
would be prime targets for those cellular proteases, in 
contrast to the less accessible Pol cleavage sites, Fig-
ure 6 and 7. The net result being that during SIV-cpz 
cross-species transmission into humans CTL selective 
pressure likely contributed to the mutation of Gag 
cleavage sites, while Pol cleavage site sequences were 
highly conserved, Figure 9. The accessibility of the 
HIV-1 Gag cleavage sites could be a strategy to direct 
the cellular immune response towards Gag to minimize 
mutation of the more structurally sensitive Pol en-
zymes that typically have ordered N-and C-termini, 
Figure 7. The remarkable ability of HIV-1 to evade the 
CTL response may be due in part to the Gag cleavage 
sites being used as bait for cellular proteases since HIV
-1 PR recognizes 24-residues of a cleavage site, with 
the ability to differentially weight substrate interac-
tions between |P12-P5| and P4-P4’ in order to accom-
modate Gag/Pol cleavage site CTL escape mutations. 
This substrate recognition strategy may allow HIV-1 
PR and other retroviral PRs to minimize the impact of 
cleavage site CTL escape mutations on PR/substrate 
interactions and consequently virus maturation 
(Phillips et al. 1991, Prince et al. 2012, Seibert et al. 
1995). 
 A complicating factor in the proposed HIV-1 
PR adaptation to mutations in Gag cleavage sites is the 
timeline; the CTL response selects for escape muta-
tions in Gag cleavage sites during a round of replica-
tion, while the selection of adaptive mutations in HIV-
1 PR for the mutated cleavage sites would take place 
in subsequent rounds of replication. Perhaps HIV-1 PR 
uses a strategy similar to that shown in silico for the 
HTLV-1 4X PR, which adapted to bulky cleavage site 
residues P4-P4' by moving the flaps away, with a con-
comitant strengthening of the S-groove contacts with 
residues |P12-P5| via the anti-parallel beta sheets, Ta-
bles 4 and 5 and Figure 10. This approach to substrates 
with mutated residues could allow the HIV-1 PR to get 
by CTL escape mutations in Gag cleavage sites during 
the same replication cycle. Then in subsequent rounds 
of replication adaptive mutations in HIV-1 PR could 
be selected for. It is interesting to note that HIV-1 PR 
secondary resistance polymorphisms were found in 
treatment naive patients, including the S-groove 
A71V/T and G73C/R mutations (Birk & Sonnerborg 
1998, Bossi et al. 1999, Kearney et al. 2008, Kozal et 
al. 1996, Rose et al. 1996b). The HIV-1 PR secondary 
resistance polymorphisms could represent an archive 
of adaptive HIV-1 PR mutations selected in response 
to CTL escape mutations in Gag cleavage sites over 
the course of an infection (Birk & Sonnerborg 1998, 
Bossi et al. 1999, Kearney et al. 2008, Kozal et al. 
1996, Servais et al. 2001). Those PR S-groove muta-
58   Journal of Molecular Biochemistry, 2017 
tions could then be selected for during subsequent in-
hibitor treatment and contribute to PR resistance. In 
untreated chronically infected patients >98% of the 
latent HIV-1 reservoir contained CTL escape muta-
tions (Deng et al. 2015). 
 The HIV-1 PR may respond to both mutations 
in substrate residues P4-P4’ and active-site inhibitors 
by reweighting substrate interactions towards the S-
grooves, since active-site inhibitors essentially mimic 
mutated substrate from the perspective of the PR in 
that both disrupt the processing of the Gag/Pol poly-
proteins. At the same time, the S-grooves may allow 
for non-covalent tethering of the HIV-1 PR to the sol-
vent exposed Gag/Pol cleavage sites, even with inhibi-
tor bound in the active-site (Figure 1), and allow for 
virion maturation at a rate concordant with the inhibi-
tor dissociation rate. Together these findings are di-
rected towards a strategy to combat HIV-1 infections 
for which current treatments are not effective (Frieden 
et al. 2015), and HTLV-1 infections for which there 
are no treatments. 
 
Conclusions 
 
Based on the finding presented here and elsewhere 
(Deshmukh et al. 2017, Laco 2015), retroviral PRs 
interact with the Gag/Pol cleavage sites using both the 
active-site and S-grooves. The PRs can weight those 
interactions towards either the active-site and cleavage 
site residues P4-P4, or S-grooves and residues |P5-
P12|, to accommodate cleavage site CTL escape muta-
tions while maintaining Gag/Pol cleavage order. Many 
retroviral PRs evolved S-groove dominated interac-
tions with substrates, and as a consequence native re-
sistance to active site inhibitors. In contrast, HIV-1 PR 
evolved a more active-site dominated interaction with 
substrates that resulted in sensitivity to active-site in-
hibitors, while retaining the ability to reweight interac-
tions towards the S-grooves and substrate residues |P5-
P12| to outcompete active-site inhibitors. 
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